Path ID: DB00619_MESH_D015466_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000068877 | imatinib | Drug |
| MESH:D016044 | Fusion Proteins, bcr-abl | Protein |
| GO:0004674 | protein serine/threonine kinase activity | MolecularActivity |
| GO:0007266 | Rho protein signal transduction | BiologicalProcess |
| GO:0008283 | cell population proliferation | BiologicalProcess |
| GO:0006915 | apoptotic process | BiologicalProcess |
| MESH:D015466 | Chronic phase chronic myeloid leukemia | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Imatinib | DECREASES ACTIVITY OF | Fusion Proteins, Bcr-Abl |
| Fusion Proteins, Bcr-Abl | POSITIVELY REGULATES | Protein Serine/Threonine Kinase Activity |
| Protein Serine/Threonine Kinase Activity | POSITIVELY CORRELATED WITH | Rho Protein Signal Transduction |
| Rho Protein Signal Transduction | POSITIVELY CORRELATED WITH | Cell Population Proliferation |
| Rho Protein Signal Transduction | NEGATIVELY CORRELATED WITH | Apoptotic Process |
| Cell Population Proliferation | POSITIVELY CORRELATED WITH | Chronic Phase Chronic Myeloid Leukemia |
| Apoptotic Process | NEGATIVELY CORRELATED WITH | Chronic Phase Chronic Myeloid Leukemia |
Comment: Imatinib also modulates other protein targets and is an indication for other malignancies (https://en.wikipedia.org/wiki/Imatinib#Medical_uses).
Reference: